MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges Article

Mansouri, Alireza, Hachem, Laureen D, Mansouri, Sheila et al. (2019). MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges . NEURO-ONCOLOGY, 21(2), 167-178. 10.1093/neuonc/noy132

Open Access International Collaboration

cited authors

  • Mansouri, Alireza; Hachem, Laureen D; Mansouri, Sheila; Nassiri, Farshad; Laperriere, Normand J; Xia, Daniel; Lindeman, Neal I; Wen, Patrick Y; Chakravarti, Arnab; Mehta, Minesh P; Hegi, Monika E; Stupp, Roger; Aldape, Kenneth D; Zadeh, Gelareh

sustainable development goals

authors

publication date

  • February 1, 2019

published in

keywords

  • ADJUVANT TEMOZOLOMIDE
  • Clinical Neurology
  • DNA METHYLATION
  • ELDERLY-PATIENTS
  • Life Sciences & Biomedicine
  • MGMT
  • MS-MLPA
  • NEWLY-DIAGNOSED GLIOBLASTOMA
  • Neurosciences & Neurology
  • O-6-METHYLGUANINE-DNA METHYLTRANSFERASE
  • OPEN-LABEL
  • Oncology
  • RADIOTHERAPY
  • RANDOMIZED PHASE-III
  • Science & Technology
  • TEMOZOLOMIDE CHEMOTHERAPY
  • diagnostic
  • glioma
  • methylation
  • molecular markers
  • prognostic

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 167

end page

  • 178

volume

  • 21

issue

  • 2